Tobias Kampfenkel
AuthID: R-00K-ANE
1
TITLE: Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma
AUTHORS: He, Jianming; Berringer, Heather; Heeg, Bart; Ruan, Haoyao; Kampfenkel, Tobias; Dwarakanathan, Harikumaran R.; Johnston, Stephen; Mendes, Joao; Lam, Annette; Bathija, Sacheeta; Mackay, Eric;
PUBLISHED: 2022, SOURCE: ADVANCES IN THERAPY, VOLUME: 39, ISSUE: 9
AUTHORS: He, Jianming; Berringer, Heather; Heeg, Bart; Ruan, Haoyao; Kampfenkel, Tobias; Dwarakanathan, Harikumaran R.; Johnston, Stephen; Mendes, Joao; Lam, Annette; Bathija, Sacheeta; Mackay, Eric;
PUBLISHED: 2022, SOURCE: ADVANCES IN THERAPY, VOLUME: 39, ISSUE: 9
INDEXED IN: 
Scopus 
WOS
Scopus WOS2
TITLE: Indirect Treatment Comparisons of Daratumumab, Pomalidomide, and Dexamethasone Versus Daratumumab, Bortezomib, and Dexamethasone or Bortezomib and Dexamethasone in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma
AUTHORS: He, Jianming; Berringer, Heather; Heeg, Bart; Kampfenkel, Tobias; Dwarakanathan, Harikumaran R.; Johnston, Stephen; Mendes, Joao; Lam, Annette; Bathija, Sacheeta; Mackay, Eric;
PUBLISHED: 2021, SOURCE: BLOOD, VOLUME: 138
AUTHORS: He, Jianming; Berringer, Heather; Heeg, Bart; Kampfenkel, Tobias; Dwarakanathan, Harikumaran R.; Johnston, Stephen; Mendes, Joao; Lam, Annette; Bathija, Sacheeta; Mackay, Eric;
PUBLISHED: 2021, SOURCE: BLOOD, VOLUME: 138
INDEXED IN: WOS
WOS